HepatectomyNCT06910852
Hepatic and Portal Vein Transection by Vascular Stapler in Open Living Donor Hepatectomy
An observational study of Hepatectomy, run by Abdalla Bashir, MD at 1 site in Jordan.
Trial summary
To enhance donor safety in living donor liver transplantation (LDLT), the use of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation has been introduced. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hepatectomy
- What is being tested?
- Vascular stapler
- Type of treatment
- Surgery or procedure
- How many people
- 17 participants
- Where
- 1 siteJordan
- Study dates
- 18 Jun 2021to 30 Nov 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing open living donor hepatectomy at Jordan Hospital.
Who may be able to join
- Patients undergoing open living donor hepatectomy
- Age ≥ 18 years, ≤ 80 years
- Written informed consent
Who cannot join
- None.
Trial locations and contacts
1 site in 1 country.
About this study
To enhance donor safety in living donor liver transplantation (LDLT), the use of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation has been introduced. This study examines the application of vascular staplers in LDLT and assesses the subsequent feasibility and safety outcomes for donors.
- Conditions
- Hepatectomy
- Being tested
- Vascular stapler
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vascular staplerProcedure or surgery
the utilization of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation for living donor liver transplantation
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-operative complications (Clavien-Dindo classification)
Measured: From enrollment to the end of treatment at 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start18 Jun 2021
- Primary completion30 Nov 2021
- Study completion30 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HepatectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abdalla Bashir, MD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Abdalla Bashir, MD, Jordan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06910852
- Sponsor's protocol ID
- STAPLER/TXS/11_20
- Status last verified
- Mar 2025
- First submitted
- 28 Mar 2025
- Last updated
- 4 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hepatic and Portal Vein Transection by Vascular Stapler in Open Living Donor Hepatectomy
- ClinicalTrials.gov ID
- NCT06910852
- Acronym / sponsor ID
- STAPLER/TXS/11_20
- Conditions
- Hepatectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- Abdalla Bashir, MDUniversity, hospital or other
- Study start
- 18 Jun 2021 (actual)
- Primary completion
- 30 Nov 2021 (actual)
- Study completion
- 30 Nov 2021 (actual)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To enhance donor safety in living donor liver transplantation (LDLT), the use of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation has been introduced. This study examines the application of vascular staplers in LDLT and assesses the subsequent feasibility and safety outcomes for donors.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing open living donor hepatectomy at Jordan Hospital.
Key inclusion criteria (3 listed)
- Patients undergoing open living donor hepatectomy
- Age ≥ 18 years, ≤ 80 years
- Written informed consent
Key exclusion criteria (1 listed)
- None.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vascular staplerthe utilization of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation for living donor liver transplantation | Procedure or surgery | – |
Primary outcome
Post-operative complications (Clavien-Dindo classification)
Time frame: From enrollment to the end of treatment at 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Hepatectomy
Not yet recruitingPhase 2
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
Not yet recruiting
RAPID for Unresectable Colorectal Liver Metastases
Colorectal Liver Metastases (CRCLM), Colorectal Neoplasms
RecruitingPhase 4
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous Pressure
Intraoperative Hypotension, Hepatectomy
Recruiting
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.
Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H)
Recruiting
Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Liver Cancer Adult, Liver Regeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatectomy, run by Abdalla Bashir, MD at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-operative complications (Clavien-Dindo classification) (time frame: From enrollment to the end of treatment at 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2025.